BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28688918)

  • 1. Time-to-Event Ratio to Predict Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation?
    Ustun C; DeFor TE; Rashidi A; Devine S; Miller J; Weisdorf D
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1804-1808. PubMed ID: 28688918
    [No Abstract]   [Full Text] [Related]  

  • 2. Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients.
    Vu K; Manjappa S; DiPersio JF; Gao F; Westervelt P; Vij R; Stockerl-Goldstein KE; Uy GL; Abboud CN; Schroeder MA; Fehniger TA; Cashen AF; Romee R
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1425-30. PubMed ID: 25840336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation.
    Jones CV; Copelan EA
    Future Oncol; 2009 May; 5(4):559-68. PubMed ID: 19450182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children.
    Uden T; Bertaina A; Abrahamsson J; Ansari M; Balduzzi A; Bourquin JP; Gerhardt C; Bierings M; Hasle H; Lankester A; Mischke K; Moore AS; Nivison-Smith I; Pieczonka A; Peters C; Sedlacek P; Reinhardt D; Stein J; Versluys B; Wachowiak J; Willems L; Zimmermann M; Locatelli F; Sauer MG
    Br J Haematol; 2020 May; 189(4):745-750. PubMed ID: 32012224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD34+ cell dose in allogeneic transplantation: weight considerations.
    Basquiera AL; Abichaín P; Damonte JC; García JJ
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):196. PubMed ID: 25270957
    [No Abstract]   [Full Text] [Related]  

  • 6. Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study.
    Fang J; Zhang R; Wang H; Hong M; Wu Q; Nie D; You Y; Zhong Z; Li W; Hu Y; Xia L
    Leuk Res; 2016 Jul; 46():61-8. PubMed ID: 27131062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic stem cell transplantation for non-de novo AML or advanced myelodysplastic syndromes: influence of GvHD and donor lymphocyte infusions on long-term outcome.
    Hemmati PG; Pfeifer K; Vuong LG; Jehn CF; Terwey TH; le Coutre P; Dörken B; Arnold R
    Bone Marrow Transplant; 2018 Jan; 53(1):101-103. PubMed ID: 28991253
    [No Abstract]   [Full Text] [Related]  

  • 8. Sequential reduced-intensity chemotherapy for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia with rare cytogenetic abnormalities transformed from Fanconi anemia.
    Inoue A; Mori A; Yamazaki S; Suzuki R; Takitani K; Tamai H
    Pediatr Int; 2018 Sep; 60(9):893-894. PubMed ID: 30255979
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia.
    Araki D; Othus M; Walter RB; Sandhu V; Sandmaier BM; Becker PS; Appelbaum FR; Estey EH
    Haematologica; 2015 Jul; 100(7):e254-6. PubMed ID: 25795719
    [No Abstract]   [Full Text] [Related]  

  • 10. GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies.
    Nazha A; Rybicki L; Abounader D; Bolwell B; Dean R; Gerds AT; Jagadeesh D; Hamilton BK; Hill BT; Kalaycio M; Liu H; Pohlman B; Sobecks R; Sekeres MA; Majhail NS
    Bone Marrow Transplant; 2016 Dec; 51(12):1642-1643. PubMed ID: 27721371
    [No Abstract]   [Full Text] [Related]  

  • 11. Allogeneic Hematopoietic Cell Transplantation for AML-A Missed Opportunity!
    O'Donnell MR
    J Natl Compr Canc Netw; 2016 Sep; 14(9):1052-3. PubMed ID: 27587618
    [No Abstract]   [Full Text] [Related]  

  • 12. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
    Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
    Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks and benefits in a personalized application of allogeneic transplantation in patients with AML in first CR.
    Versluis J; Cornelissen JJ
    Semin Hematol; 2019 Apr; 56(2):164-170. PubMed ID: 30926093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is timing everything?
    Rizzieri D
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):145-6. PubMed ID: 24342395
    [No Abstract]   [Full Text] [Related]  

  • 15. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
    Takami A; Yano S; Yokoyama H; Kuwatsuka Y; Yamaguchi T; Kanda Y; Morishima Y; Fukuda T; Miyazaki Y; Nakamae H; Tanaka J; Atsuta Y; Kanamori H
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1785-90. PubMed ID: 25034960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated Extramedullary Relapse of Acute Leukemia after Allogeneic Stem Cell Transplantation: Different Kinetics and Better Prognosis than Systemic Relapse.
    Shem-Tov N; Saraceni F; Danylesko I; Shouval R; Yerushalmi R; Nagler A; Shimoni A
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1087-1094. PubMed ID: 28396161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.
    Valcárcel D; Martino R
    Curr Opin Oncol; 2007 Nov; 19(6):660-6. PubMed ID: 17906468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.
    Ishida H; Kato M; Kudo K; Taga T; Tomizawa D; Miyamura T; Goto H; Inagaki J; Koh K; Terui K; Ogawa A; Kawano Y; Inoue M; Sawada A; Kato K; Atsuta Y; Yamashita T; Adachi S
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2141-2147. PubMed ID: 26271192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Leukemia.
    Inagaki J; Noguchi M; Kurauchi K; Tanioka S; Fukano R; Okamura J
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):300-306. PubMed ID: 26371373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
    Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
    Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.